Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Wung

Cardiovascular Disease Brentwood, CA Medical Doctor

NPI 1407240096 CMS profile 5690031

2400 Balfour Rd Ste 201, Brentwood, CA 94513

Open in the dashboard

General payments

$10,873

330 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Wung of Brentwood, CA is reported in the CMS Open Payments database as having received $10,873 across 330 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $882 30
2024 General $2,073 55
2023 General $1,842 82
2022 General $1,840 75
2021 General $1,425 21
2020 General $1,008 26
2019 General $1,802 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Wung
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to William Wung were reported at $882. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year William Wung Cardiovascular Disease median Middle half National median
2019 $1,802 $450 $127–$1,392 $163
2020 $1,008 $242 $77–$751 $114
2021 $1,425 $335 $101–$1,037 $132
2022 $1,840 $395 $121–$1,211 $149
2023 $1,842 $443 $136–$1,283 $160
2024 $2,073 $450 $136–$1,323 $164
2025 $882 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,852 42 payments
  2. Abbott Laboratories $1,663 21 payments
  3. Boston Scientific Corporation $1,329 28 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $1,083 42 payments
  5. Biotronik Inc. $764 12 payments
  6. Janssen Pharmaceuticals, Inc $530 18 payments
  7. Novartis Pharmaceuticals Corporation $411 20 payments
  8. Amgen Inc. $406 21 payments
  9. Chiesi USA, Inc. $349 8 payments
  10. AstraZeneca Pharmaceuticals LP $326 19 payments
  11. Other $2,159 99 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,919 322 payments
  2. Travel and Lodging $698 3 payments
  3. Education $256 5 payments
Products named General payments · program years 2019–2025
  1. LifeVest $1,852 42 payments
  2. JARDIANCE $891 34 payments
  3. XARELTO $530 18 payments
  4. SYNERGY Pain Management $376 7 payments
  5. Repatha $358 18 payments
  6. LEQVIO $355 18 payments
  7. KENGREAL $289 5 payments
  8. Arcalyst $275 17 payments
  9. Synergy Stents $268 7 payments
  10. FARXIGA $237 13 payments
  11. Other $5,073 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

3,521

Median for Cardiology: 2,533

Drug cost

$823,458

Median for Cardiology: $485,213

Branded share of claims

22.4%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 227 $326,681
Jardiance Empagliflozin Brand 113 $151,288
Xarelto Rivaroxaban Brand 94 $135,805
Entresto Sacubitril/Valsartan Brand 36 $64,400
Repatha Sureclick Evolocumab Brand 40 $40,655
Farxiga Dapagliflozin Propanediol Brand 15 $23,420
Brilinta Ticagrelor Brand 13 $15,589
Ozempic Semaglutide Brand 15 $13,801
Rosuvastatin Calcium Generic 357 $7,985
Ezetimibe Generic 125 $5,235

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$325,236

Of which drugs: $8,631

Medicare patients

1,958

Average age 75

Services billed

5,969

1,031 women, 927 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Diabetes 43%
Ischemic heart disease 42%
Chronic kidney disease 40%
Heart failure 38%
Atrial fibrillation 38%
Depression 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 15 60 $502

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $152
  • Lilly USA, LLC $36
$188 113 —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $115
$115 — —
Repatha
  • Amgen Inc. $83
$83 40 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $59
$59 227 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $49
$49 15 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

330 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record